Protagonist Therapeutics, Inc. announced the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024. Closing of the transaction was contingent on completion of review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the United States. Protagonist will receive the $300 million upfront payment associated with the transaction in the second quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.17 USD | -4.68% | +11.27% | +44.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.66% | 2.04B | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda